16 February, 2022
Chordate Medical is now listed on the Nasdaq First North Growth Market. At the bell ringing ceremony on February 15th, Chairman of the Board Henrik Rammer gave a short speech about the company and its future, whereafter company CEO Anders Weilandt rang the Nasdaq bell.
Chordate's change of stock exchange list is judged by the company's board to increase the company's awareness both in Sweden and internationally, make it easier for industrial investors to become shareholders, and have a positive impact on the company's relationships with partners and potential customers.
If you want to read our press releases, there are available in the Investor Relations section or by clicking the link below.
For questions about Chordate's share price or other investment-related topics, please see if the answer is here.
For questions about the medical effects of the K.O.S treatment, please see if the answer is here.
To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.
Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company's share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.